KN
Kannappan Nagappan
About Kannappan Nagappan
Data last updated:
Kannappan Nagappan is a Director at Steril-Gene Life Sciences Private Limited (since 2014), Director at Madras Pharma Holdings Private Limited (since 2014) and Director at Anphar Organics Private Limited (since 2014), and holds 3 more current directorships. The companies operate in Pharma and Financial Services. The 5 current companies with reported revenue have a combined latest revenue of ₹509 Cr; the largest is Steril-Gene Life Sciences Private Limited at ₹404 Cr (FY 2025). Earlier, Kannappan Nagappan was a Director at Softgel Healthcare Private Limited (2014–2022).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 10 Mar 2014 | 2007 | ₹404 Cr (FY 2025) | Active | |
| Director | 10 Mar 2014 | 2010 | ₹43.68 Cr (FY 2025) | Active | |
| Director | 07 Aug 2014 | 1994 | ₹36.70 Cr (FY 2025) | Active | |
| Director | 03 Feb 2015 | 2015 | ₹24.43 Cr (FY 2025) | Active | |
| Director | 10 Mar 2014 | 2004 | ₹1.2 Lakh (FY 2025) | Active | |
| Director | 11 May 2015 | 2015 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 10 Mar 2014 | 2003 | ₹327 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Kannappan Nagappan
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Kannappan Nagappan
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kannappan Nagappan
Kannappan Nagappan currently holds 6 directorships: Steril-Gene Life Sciences Private Limited (Director, since 10 Mar 2014, revenue ₹404 Cr (FY 2025)); Madras Pharma Holdings Private Limited (Director, since 10 Mar 2014, revenue ₹43.68 Cr (FY 2025)); Anphar Organics Private Limited (Director, since 07 Aug 2014, revenue ₹36.70 Cr (FY 2025)); Sunberg Life Sciences Private Limited (Director, since 03 Feb 2015, revenue ₹24.43 Cr (FY 2025)); Maral Health Care Private Limited (Director, since 10 Mar 2014, revenue ₹1.2 Lakh (FY 2025)); and 1 more.
Kannappan Nagappan was first appointed on 10 Mar 2014 as Director at Steril-Gene Life Sciences Private Limited. The most recent appointment on record is 11 May 2015 at Madras Pharmaceuticals Private Limited.
The 5 current companies of Kannappan Nagappan that report revenue have a combined latest revenue of ₹509 Cr: Steril-Gene Life Sciences Private Limited ₹404 Cr (FY 2025); Madras Pharma Holdings Private Limited ₹43.68 Cr (FY 2025); Anphar Organics Private Limited ₹36.70 Cr (FY 2025); Sunberg Life Sciences Private Limited ₹24.43 Cr (FY 2025); Maral Health Care Private Limited ₹1.2 Lakh (FY 2025).
Kannappan Nagappan held 1 earlier board appointment: Softgel Healthcare Private Limited (Director, 10 Mar 2014 to 08 Sep 2022).
The current boards of Kannappan Nagappan's companies include Alagappan (Steril-Gene Life Sciences Private Limited), Chanpreet Singh Anand (Steril-Gene Life Sciences Private Limited), Dennis Dizon Balajadia (Steril-Gene Life Sciences Private Limited), Dick Dizon Balajadia (Steril-Gene Life Sciences Private Limited), Lloyd Dizon Balajadia (Steril-Gene Life Sciences Private Limited), Manohar Srivignesh (Steril-Gene Life Sciences Private Limited), among others.